B+
Bull case
20%
Probability
Target price
$0.55
Analysis reference price unavailable
Analysis 2026-08-26 · RankAlpha Sentiment Codex
PDSB
PDS BiotechnologyDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$0.22
Analysis reference price unavailable
Analysis 2026-08-26 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.07
Analysis reference price unavailable
Analysis 2026-08-26 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-26
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+41.5
Score
AI commentary
Primary-source sentiment is mixed: encouraging PDS0301 clinical data and a clearer capital-allocation focus are offset by the discontinued Phase 3 program, workforce reduction, COO departure, $5.6 million cash balance, and substantial quarterly loss. Coverage is low and largely recap-oriented; social, options, short-interest, employee, analyst-revision, and verified post-print market-reaction evidence are unavailable or insufficient, so missing data are not positive evidence.
RankAlpha Sentiment Codex - 2026-08-26
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-11-24eventExecution of PDS0301-focused strategyHigh impact
PDS Biotech has prioritized PDS0301 as its lead program, ceased further internal investment in PDS0101, and discontinued the VERSATILE-003 Phase 3 trial. Successful resource concentration and continued PDS0301 progress could improve strategic clarity, but the shift also increases pipeline concentration [#SEC-8K-2026-08-13] [#PR-EARNINGS-2026-08-13].
2026-11-24catalystCost reduction and liquidity pressureHigh impact
The company expects a workforce reduction affecting approximately 36% of employees, an estimated $842,000 third-quarter severance charge, and the COO departure. Q2 cash was $5.6 million against a $9.8 million quarterly net loss, making financing and execution the key near-term risks [#SEC-8K-2026-08-25] [#SEC-8K-2026-08-13].
2027-08-26catalystPDS0301 metastatic colorectal cancer follow-throughHigh impact
Stage 1 mCRC data showed a 77.8% six-month objective response rate in 7 of 9 patients, approximately 80% 24-month survival, and median extrahepatic PFS not reached. The dataset is small, open-label, single-center, and non-randomized, so confirmatory development remains the key value driver [#SEC-8K-2026-08-13].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-26 • Updated nightlySource: Internal modelMethodology